Alaunos Therapeutics Inc (TCRT)
3.11
-0.43
(-12.15%)
USD |
NASDAQ |
Sep 27, 16:00
3.00
-0.11
(-3.54%)
After-Hours: 20:00
Alaunos Therapeutics SG&A Expense (Annual): 12.22M for Dec. 31, 2023
SG&A Expense (Annual) Chart
Historical SG&A Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 12.22M |
| December 31, 2022 | 13.14M |
| December 31, 2021 | 27.56M |
| December 31, 2020 | 27.66M |
| December 31, 2019 | 19.53M |
| December 31, 2018 | 19.92M |
| December 31, 2017 | 14.80M |
| December 31, 2016 | 14.38M |
| December 31, 2015 | 17.65M |
| December 31, 2014 | 12.17M |
| December 31, 2013 | 15.66M |
| December 31, 2012 | 19.52M |
| Date | Value |
|---|---|
| December 31, 2011 | 14.98M |
| December 31, 2010 | 11.64M |
| December 31, 2009 | 7.567M |
| December 31, 2008 | 8.374M |
| December 31, 2007 | 9.578M |
| December 31, 2006 | 8.720M |
| December 31, 2005 | 4.194M |
| December 31, 2004 | 3.582M |
| December 31, 2003 | 0.1606M |
| December 31, 2002 | 0.00 |
| December 31, 2001 | 0.0001M |
SG&A Expense Definition
SG&A expense (short for Selling, General and Administrative expense) is a line item on the income statement, though sometimes sales and marketing expenses are reported separately from general and administrative expenses.
SG&A Expense (Annual) Range, Past 5 Years
12.22M
Minimum
2023
27.66M
Maximum
2020
20.02M
Average
19.53M
Median
2019
SG&A Expense (Annual) Benchmarks
| Perspective Therapeutics Inc | 21.06M |
| Oragenics Inc | 5.452M |
| Cocrystal Pharma Inc | 5.99M |
| Cara Therapeutics Inc | 27.65M |
| Jaguar Health Inc | 23.05M |